AT1R blockers could prevent the progress of liver injury induced by D- galactosamine in rats with liver failure, resulting in the improvement of survival rate, the decrease of liver enzymes, the decrease of liver histopathology and tissue-specific inhibitors of metalloproteinases [41]. This evidence concerns the gene AGTR1 and Hepatic failure.